Ana Rita Branco Marques dos Santos

2021/01 -

CHART - Characterization of Retinal disease progression in eyes with NPDR in diabetes Type 2 using non-invasive procedures

NCT04636307

Post-doc

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2020/06 - 2021/01

RHONE-X - A Multicenter, open-Label extension Study to evaluate the log-term safety and tolerability of faricimab in patients with diabetic macular edema

NCT04432831

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2020/07 -

RECOGNISED - Retinal and cognitive dysfunction in type 2 diabetes: unravelling the common pathways and identification of patients at risk of dementia

NCT04281186

Researcher

Vall d'Hebron Institut de Recerca Grup de Recerca Diabetis i Metabolisme

2019/09/01 - 2021/04/01

PANDA-1 Study - A Multicenter, Double Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration

NCT03577899

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2019 -

ROBIN / BI 1386-0012 - A study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of orally administered BI 1467335 for 12 weeks with a 12 week follow up period in patients with NPDR without center-involved DME.

ClinicalTrials.gov: NCT03238963

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Boehringer Ingelheim Auslandsbeteiligungs GmbH

2019 -

OPTIMUM LT / AC-058B303 - Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis.

ClinicalTrials.gov: NCT03232073

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Actelion Clinical Research Inc

2018 -

KESTREL / CRTH258B2301 - A two-year, three-arm, randomized, double-masked, multicentre, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema.

ClinicalTrials.gov: NCT03481634

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2018 -

CORDIS / CEC/194/2018 - Characterization of Retinal vascular disease in eyes with mild to moderate NPDR in Diabetes type 2, using novel non-invasive Imaging methods, in a longitudinal, prospective and interventional Study of 2 years.

ClinicalTrials.gov: NCT03696810

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Fundação para a Ciência e a Tecnologia

2018 -

MACUSTAR / ECR-AMD-2017-13 - Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD).

ClinicalTrials.gov: NCT03349801

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: European Union

2018 -

Xplore / XBR1001 - Xplore: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration.

ClinicalTrials.gov: NCT03805100

Technical development

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Xbrane Biopharma AB

2018 -

PIONEER / GS030_CLIN_001 - A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa.

ClinicalTrials.gov: NCT03326336

Technical development

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: GenSight Biologics SA

2018 -

THR-317-002 - A study to evaluate the efficacy and safety of intravitreal THR-317 when administered alone or in combination with Lucentis®, in DME patients with a poor or no response to anti-VEGF treatment.

ClinicalTrials.gov: NCT03499223

Technical development

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Oxurion

2018 -

RHINE / GR40398 - A phase III, multicentre, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema.

ClinicalTrials.gov: NCT03622593

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: F Hoffmann-La Roche AG

2018 -

BAY 1163877/17403 - Evaluate efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.

ClinicalTrials.gov: NCT03410693

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Bayer AG

2017 - 2018

DAYBREAK / I8D-MC-AZET - A randomized , double-blind, placebo-controlled and delayed-start study of LY3314814 in Mild Alzheimer´s Disease Dementia.

ClinicalTrials.gov: NCT02783573

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Eli Lilly and Company

2017 - 2017

OMASPECT / GX30191 - A multi-center, open label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with Geographic atrophy secondary to Age-related Macular Degeneration.

ClinicalTrials.gov: NCT02745119

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: F Hoffmann-La Roche AG

2017 - 2018

STAR / CEC/008/2016 - STAR- Development of a Model for Advanced Screening for Timely Treatment of Age-Related Eye Diseases.

CEC/008/2016

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2016 -

DAYBREAK / RPC01-3001 - A multi-site, open-label extension Trial of Oral RPC1063 in relapsing Multiple Sclerosis.

ClinicalTrials.gov: NCT02576717

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Celgene International II Sàrl

2016 -

OPTIMUM / AC-058301 - Multicenter, randomised, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis.

AC-058301

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Actelion Clinical Research Inc

2016 - 2017

AMDIncidence_CPT / 4C-2016-09 - Five-year incidence of Age-related Macular Degeneration in the central region of Portugal.

ClinicalTrials.gov: NCT02748824

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2016 -

VIOLET / BAY86-5321/17613 - An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety and tolerability of three different treatment regimens of 2 mg aflibercept to subjects with DME.

ClinicalTrials.gov: NCT02818998

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Bayer AG

2016 -

PROGRESS / CEC/007/16 - Progression of Diabetic Retinopathy. Identification of Signs and Surrogate outcomes.

ClinicalTrials.gov: NCT03010397

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2016 - 2017

BI 1322.20 - A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impairment due to center-involved DME.

ClinicalTrials.gov: NCT02732951

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Boehringer Ingelheim Auslandsbeteiligungs GmbH

2016 - 2018

PADCiclo / MC2-03-C1 - Evaluate the Safety and Efficacy of PAD Ciclosporin (CsA 0.06% and 0.03%) Ophthalmic Dispersion Administered Once Daily in Combination with Lubricant Therapy in Moderate to Severe Dry Eye Patients.

MC2-03-C1

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Mc2 Biotek Group

2016 - 2018

THR-317-001 - A Phase 2, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular oedema (DME).

ClinicalTrials.gov: NCT03071068

Technical development

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: ThromboGenics NV

2015 - 2017

SUNBEAM / RPC01-301 - A phase III, multicenter, randomized, double-blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclerosis patients.

ClinicalTrials.gov: NCT02294058

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2015 -

EYEMARKER / 4C-2015-08 - Characterization of poential biomarkers of Eye Disease and Vision Loss.

ClinicalTrials.gov: NCT02500862

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2015 - 2016

PREMED / NL 42463.068.12 - Prevention of Macular Edema after cataract surgery.

ClinicalTrials.gov: NCT01774474

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2015 - 2017

SPECTRI / GX29185 - A phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to AMD.

ClinicalTrials.gov: NCT02247531

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: F Hoffmann-La Roche AG

2015 -

IRISS / M-01-12-001- A phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to AMD.

ClinicalTrials.gov: NCT01998412

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alimera Sciences Ltd

2015 - 2016

IN0654 - Metabolomics, Genetics and Environment – a novel integrative approach to Age-Related Macular Degeneration.

IN0654

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Fundação para a Ciência e a Tecnologia

2015 - 2017

THEA-UNAV1/14 - An Interventional, multicentre, randomized study of nutritional supplements in unilateral wet AMD.

THEA-UNAV1/14

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Laboratoires Théa

2015 - 2016

OCTA / 4C-2015-07 - Clinical evaluation of noninvasive OCT Angiography using a Zeiss OCT.

ClinicalTrials.gov: NCT02391558

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2015 - 2017

CEC 006/2015 - Genotypic and Phenotypic characterization of retinal angiomatous proliferation (RAP) lesions.

CEC 006/2015

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2015 - 2018

ATLANTIC / ECR-AMD-2015-09 - A randomized, double-masked, sham-controlled phase 4 study of efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic therapy in patients with PCV.

ClinicalTrials.gov: NCT02495181

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2015 - 2018

HARRIER / RTH258-C002 - A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects with Neovascular AMD.

ClinicalTrials.gov: NCT02434328

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alcon Research Ltd

2015 - 2017

AQUA / BAY86-5321/17850 - Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With DME During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment.

ClinicalTrials.gov: NCT02581995

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Bayer AG

2015 -

AZURE / BAY86-5321/16598 - An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept using two different treatment regimens to subjects with neovascular AMD.

ClinicalTrials.gov: NCT02540954

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Bayer AG

2014 - 2015

TREND / CRFB002A2411 - A 12-month, phase IIIb, randomized, visual acuity assessor-masked, multicenter study assessing efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in patients with neovascular AMD.

ClinicalTrials.gov: NCT01948830

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2014 - 2015

PROTEUS / ECR-RET-2013-05 – Phase II/III study to assess efficacy and safety of ranibizumab 0.5 mg iv injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with HR-PDR.

ClinicalTrials.gov: NCT01941329

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2014 - 2014

SPORT / ECR-GLC-2013-06 -Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study.

ClinicalTrials.gov: NCT01975714

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2014 - 2017

EPOCH / MK-8931-017-03 - A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer’s Disease.

MK-8931-017-03

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Merck Sharp and Dohme

2014 - 2015

ARTES / ECR-RET-2014-07- A Collaborative Retrospective Trial on the Efficacy and Safety of intravitreal dexamethasone implant (Ozurdex) in patients with Diabetic Macular Edema (DME). The European DME Registrar Study.

ClinicalTrials.gov: NCT02121197

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2014 - 2017

SALT / CRFB002ADE23 - A study to compare efficacy of ranibizumab PRN vs aflibercept bimonthly on retinal thickness stability till month 6 of treatment and explore functional outcomes up to month 12 in patients with neovascular AMD.

ClinicalTrials.gov: NCT01958918

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2014 - 2015

JETREA / M-13-056 - Assessment of Anatomical and Functional Outcomes in Patients Treated with Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA).

ClinicalTrials.gov: NCT02035748

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alcon Research Ltd

2014 - 2017

FOVISTA / OPH1004B - A Trial to Establish Safety and Efficacy of Intravitreous Administration of Fovista® Administered in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy in Subfoveal Neovascular AMD.

ClinicalTrials.gov: NCT01940887

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Ophthotech Corporation

2014 - 2015

RESPOND / 4C-2014-06 - A study of the effect and safety of Iluvien® in chronic diabetic macular edema patients considered insufficiently responsive to available therapie with or without intravitreal corticosteroid therapy.

ClinicalTrials.gov: NCT02359526

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2013 - 2015

Eyeguard A / CL3-78989-005 - A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis.

ClinicalTrials.gov: NCT01684345

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Servier Laboratories Ltd

2013 - 2015

Eyeguard B / CL3-78989-002 - A randomised, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease Uveitis.

ClinicalTrials.gov: NCT01965145

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Servier Laboratories Ltd

2013 -

EXPAND / CBAF313A2304 - A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

ClinicalTrials.gov: NCT01665144

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2013 - 2014

POLARIS / 16459 – A prospective non-interventional study to assess the effectiveness of existing anti-vascular endothelial growth factor (Anti-VEGF) treatment regimens in patients with diabetic macular edema (DME) with central involvement.

ClinicalTrials.gov: NCT01771081

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Bayer AG

2013 - 2015

OCTAVE / CRFB002A2405 - A 24-study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional / anatomical criteria, in patients with neovascular AMD.

ClinicalTrials.gov: NCT01780935

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2013 - 2015

Eyeguard C / CL3-78989-006 - A Randomized, Double-masked, Placebo-controlled Study of SafetY and Efficacy of Gevokizumab in the Treatment of Non-infectious IntermeDiate, Posterior, or Pan- uveitis Currently Controlled with Systemic Treatment.

linicalTrials.gov: NCT01747538

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Servier Laboratories Ltd

2013 - 2016

CHARTRES / 4C-2013-05 - Characterization of Eyes with Diabetic Macular Edema that show different Treatment Response to Intravitreal anti-VEGF.

ClinicalTrials.gov: NCT01947881

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2013 - 2015

MINERVA / CRFB002G2301 - A study to evaluate efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV).

ClinicalTrials.gov: NCT01840410

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2013 - 2013

BENEFIT - Long-term, follow-up study (16401) of the BENEFIT (304747),BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate theprogress of patients with first demyelinating event suggestive of multiple sclerosis.

ClinicalTrials.gov: NCT01795872

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Bayer AG

2012 - 2013

REVIEW / 16378 - A Retrospective non-interventional study to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens in patients with wet age-related macular degeneration.

ClinicalTrials.gov: NCT01933152

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Bayer AG

2012 - 2015

EUROCONDOR / 4C-2011-02 - Neurodegeneration as an early event in the pathogenesis of DR: A trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest DR.

ClinicalTrials.gov: NCT01726075

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: European Union

2012 - 2014

206207-024 - A Multi-center, open-label, randomized study comparing the efficacy and safety of 700µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic macular Edema.

ClinicalTrials.gov: NCT01492400

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Allergan AG

2012 - 2014

CRYSTAL / CRFB002E2401 - A study assessing efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with ranibizumab applied as monotherapy in patients with visual impairment due to macular edema secondary to CRVO.

ClinicalTrials.gov: NCT01535261

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2012 - 2016

LUMINOUS™ / RFB002A2406 - Study to observe the effectiveness and safety of ranibizumab through individualized patient treatment and associated outcomes.

ClinicalTrials.gov: NCT01318941

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2012 - 2015

C-TRACER 1 / 4C-2012-02 - Biomarkers of Diabetic Retinopathy Progression.

ClinicalTrials.gov: NCT01607190

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2012 - 2015

CL2-38093-012 - Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer’s Disease.

CL2-38093-012

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Servier Laboratories Ltd

2012 - 2014

028A - Data analysis regarding OCT and Color Fundus Photography in patients with Multiple Sclerosis.

028A

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2011 - 2013

RETAIN / CRFB002D2304 - A trial assessing Efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” Treatment Algorithms vs. 0.5 mg ranibizumab as needed in patients with macular edema and visual Impairment secondary to Diabetes.

ClinicalTrials.gov: NCT01171976

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2011 - 2014

PICO / CRFB002APT05 - Investigational Observacional Portuguese Project with Lucentis in Age macular Degeneration (AMD) among 50 ophthalmologic Centers for 12 months.

CRFB002APT05

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis AG

2011 - 2012

SANTEN / 201051 - A study to compare efficacy and safety of preservative-free fixed dose combination of tafluprost and timolol eye drops to those of tafluprost and timolol eye drops given concomitantly in patients with open angle glaucoma.

ClinicalTrials.gov: NCT01306461

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Santen Oy

2011 - 2012

C-10-040 - Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Fixed Combination, Suspension compared to Brinzolamide 10 mg/mL, Suspension and Brimonidine 2 mg/mL, Solution in Open-Angle Glaucoma/Ocular Hypertension.

ClinicalTrials.gov: NCT01310777

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alcon Research Ltd

2011 - 2014

DIAMARKER / 4C-2011-01 - Phenotypes of NPDR in Diabetes type 2 patients identified by OCT, Colour Fundus Photography, Fluorescein Leakage and Multifocal Electrophysiology (DIAMARKER Project).

ClinicalTrials.gov: NCT01440660

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2011 - 2012

RADIANCE / CRFB002F2301 - A study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia.

ClinicalTrials.gov: NCT01217944

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2011 - 2015

BRIGHTER / CRFB002E2402 - A study assessing efficacy and safety of PRN dosing regimen with ranibizumab applied as monotheraphy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in macular edema secondary to BRVO.

ClinicalTrials.gov: NCT01599650

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2011 - 2013

C-10-083 - Safety and Efficacy Study of ESBA1008 versus LUCENTIS® for the Treatment of Exudative Age-Related Macular Degeneration.

ClinicalTrials.gov: NCT01304693

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alcon Research Ltd

2010 - 2012

PTDC/SAU- BEB/103151/2008 - Evaluation of blood-retinal barrier functional alterations by optical coherence tomography.

ClinicalTrials.gov: NCT01220804

Funders: Fundação para a Ciência e a Tecnologia

2010 - 2010

LT2345 - Efficacy and safety assessment of T2345 unpreserved eyedrops versus Xalatan® in ocular hypertensive or glaucomatous patients.

ClinicalTrials.gov: NCT01156012

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Laboratoires Théa

2010 - 2013

CC-02-2009 - Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen (pegaptanib 0.3mg) plus panretinal photocoagulation (PRP) and PRP (monotheraphy) in the treatment of patient with high risk PDR.

ClinicalTrials.gov: NCT01281098

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2010 - 2014

LUCENTIS PDR / CRFB002DPT04T - Study to assess eficacy and safety of Lucentis® monotheraphy compared with Lucentis® plus panretinal photocoagulation (PRP) and PRP (monotheraphy) in the treatment of patients with high risk PDR.

ClinicalTrials.gov: NCT01280929

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2010 - 2013

RET02 / ECR-RET-2010-02 - Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non-invasive procedures.

ClinicalTrials.gov: NCT01145599

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2010 - 2011

DUOTRAV - An evaluation of the Ocular Surface Health in subjects using DuoTrav APS eye drops solution versus Xalacom® eye drops solution.

ClinicalTrials.gov: NCT00912054

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alcon Research Ltd

2010 - 2013

190342-033D - A multicenter, patient-masked, safety extension study to evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.

ClinicalTrials.gov: NCT01080209

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Allergan AG

2010 - 2011

GANFORT / MAFAGNOPHGLA010 - A Study to evaluate eficacy and safety of Bimatoprost/Timolol fixed combination vs Latanoprost in treatment-Naive patients with Open-Angle Glaucoma at high risk of Glaucomatous progression.

ClinicalTrials.gov: NCT01243567

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Allergan AG

2010 - 2012

PTDC/SAU- BEB/103151/2008 - Evaluation of blood-retinal barrier functional alterations by optical coherence tomography.

ClinicalTrials.gov: NCT01220804

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Fundação para a Ciência e a Tecnologia

2010 - 2017

FTY 2399 / CFTY720D2399 - A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis.

ClinicalTrials.gov: NCT01201356

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2010 - 2014

M10-877 - A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate, Posterior, or Pan-uveitis.

ClinicalTrials.gov: NCT01138657

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Abbott Laboratories

2010 - 2014

M10-880 - A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate Posterior, or Pan-uveitis.

ClinicalTrials.gov: NCT01124838

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Abbott Laboratories

2010 - 2018

M11-327 - A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate, Posterior, or Pan-uveitis.

ClinicalTrials.gov: NCT01148225

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Abbott Laboratories

2009 - 2012

PTDC/SAU-OSM/103226/2008 - Observational study to assess Genotypes/Phenotypes correlations in type-2 diabetic retinopathy.

ClinicalTrials.gov: NCT01228981

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Fundação para a Ciência e a Tecnologia

2009 - 2012

GATE / C-08-36 - The safety and efficacy of AL-8309B ophthalmic solution for the treatment of geographic atrophy secondary to age-related macular degeneration.

ClinicalTrials.gov: NCT00890097

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alcon Research Ltd

2009 - 2011

190342-032D - A study to evaluate safety and effects on Retinal Structure and Visual Function of Brimonidine (Brimonidine Tartrate PS DDS) applicator system in patients with Geographic atrophy from AMD.

ClinicalTrials.gov: NCT00658619

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Allergan AG

2008 - 2010

Brimo RP / 190342-028D - A Study to Evaluate Safety and Effects on Visual Function of 100ug, 200 ug, and 400 ug Brimonidine Tartrate PS DDS Applicator System in Patients with Retinitis Pigmentosa.

ClinicalTrials.gov: NCT00661479

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Allergan AG

2008 - 2014

IVABRADINA / CL3-16257-067 - Long term (3 years) (...) efficacy and safety of ivabradine administered at therapeutic recommended doses (2.5/5/7.5 mg b.i.d.) on top of anti anginal background therapy, to patients with chronic stable angina pectoris.

CL3-16257-067

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Les Laboratoires Servier SAS

2008 - 2010

A9011051 - Early Markers of choroidal neovascularization (CNV) in fellow eyes of patients with Age-Related Macular Degeneration (AMD) and CNV in one eye.

ClinicalTrials.gov: NCT00902785

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Pfizer Inc

2008 - 2008

A6111139 - A phase 1, Open-Label study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated with Latanoprost 0.005%.

ClinicalTrials.gov: NCT00638742

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Pfizer Inc

2008 - 2009

206207-016 - A Study to Assess Safety and Efficacy of 700µg Dexamethasone PSDDS Applicator System as Adjuntive Therapy to Lucentis® Compared with Lucentis® Alone in the Treatment of Patients with CNV Secondary to AMD.

ClinicalTrials.gov: NCT00511706

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Allergan AG

2008 - 2009

A6111137 - A phase 3 Prospective, Randomized, Double-Masked, 12-week, parallel group Study evaluating the efficacy and safety of Latanoprost and Timolol in Pediatric subjects with Glaucoma.

ClinicalTrials.gov: NCT00716859

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Pfizer Inc

2008 - 2011

VIEW2 / 311523 - A randomized, double-masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trop-Eye in subjects with neovascular AMD.

ClinicalTrials.gov: NCT00637377

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Bayer AG

2007 - 2010

SECURE / CRFB002A2402 - A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in patients with subfoveal choroidal neovascularization secondary to AMD.

ClinicalTrials.gov: NCT00504959

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2007 - 2009

COBALT / ACU301 - A Phase 3 Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative AMD.

ClinicalTrials.gov: NCT00499590

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: OPKO Health Inc

2007 - 2011

EOP1013 – A Phase 2/3 Trial to Compare Safety and Efficacy of Intravitreous Injections of Pegaptanib Sodium (Macugen®), Given as Often as Every 6 Weeks for 3 years, to Sham Injections, in Subjects with DME involving the Center of Macula.

ClinicalTrials.gov: NCT00605280

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Pfizer Inc

2007 - 2013

MEAD / 206207-010 - A 3-years, phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 micrograms and 350 micrograms Dexamethasone (DEX PS DDS) Aplicator System in the Treatment of Patients with DME.

ClinicalTrials.gov: NCT00168389

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Allergan AG

2007 - 2009

EMD05-03 - Study of the Efficacy and Safety of Travatan® Therapy compared with Cosopt® Therapy in Patients with Open-Angle Glaucoma or Ocular Hypertension.

ClinicalTrials.gov: NCT00471068

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alcon Research Ltd

2007 - 2011

FTY720II / CFTY720D2302 - A study comparing the efficacy and afety of fingolimod (FTY720) administered orally once daily vs interferon ß-1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis.

ClinicalTrials.gov: NCT00340834

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2006 - 2006

C-04-65 - Nepafenac 0,1% Eye Drops, suspension compared to ketorolac Trometamol 0,5% Eye Drops, solution and placebo (nepafenac vehicle) for the prevention and treatment of ocular inflammation and ocular pain associated with cataract surgery.

ClinicalTrials.gov: NCT00405730

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alcon Research Ltd

2006 - 2008

EXCITE / CRFB002A2302 - A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3mg and 0.5mg) administered as two dosing regimens in patients with subfoveal CNV secondary to AMD.

ClinicalTrials.gov: NCT00275821

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2006 - 2009

A5751017 - A 102-week, open label, multicenter trial to investigate the efficacy of macugen for the preservation of visual function in subjects with neovascular AMD and to assess the benefit of treating early CNV.

ClinicalTrials.gov: NCT00327470

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Pfizer Inc

2006 - 2008

SUSTAIN /CRFB002A2303 - A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy and of ranibizumab (0.3mg) in patients with subfoveal choroidal neovascularization secondary to AMD.

ClinicalTrials.gov: NCT00331864

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2006 - 2008

EOP1010 - An open label, non-comparative protocol for the use of pegaptanib sodium injection every 6 weeks in patients with exudative age-related macular degeneration.

ClinicalTrials.gov: NCT00088192

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Eyetech Pharmaceuticals

2006 - 2009

POSURDEX UVEITES / 206207-014 - A study to assess safety and efficacy of dexamethasone DEX PS DDS applicator system compared with sham DEX PS DDS applicator system in non-infectious ocular inflammation in patients with intermediate uveitis.

ClinicalTrials.gov: NCT00333814

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Allergan AG

2006 - 2008

CNV-Markers / A9010002 - Characterization of early markers of choroidal neovascularization in fellow eyes of patients with AMD and CNV in one eye. Two-year follow-up.

ClinicalTrials.gov: NCT00801541

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

2006 - 2010

FAME / C-01-05-001 - A randomized, double-masked, dose-finding comparison of the safety and efficacy of ASI-001A 0.5 ug/day and ASI-001B 0.2 ug/day fluocinolone acetonide intravitreal inserts to sham injection in subjects with DME.

ClinicalTrials.gov: NCT00344968

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alimera Sciences Inc

2005 - 2008

RESOLVE / CRFB002D2201 - A randomized phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of DME with center involvement.

ClinicalTrials.gov: NCT00284050

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2005 - 2011

FTY720 / CFTY720D2201 - An extension, randomized, placebo-controlled, parallel-group, multicenter study evaluating safety, tolerability and effect on MRI lesion parameters of FTY720 vs placebo in patients with relapsing multiple sclerosis.

ClinicalTrials.gov: NCT00333138

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2005 - 2011

MBCU / B7A-MC-MBCU - The effect of Ruboxistaurin on Clinically significant macular edema in patients with diabetes Mellitus, as assessed by optical coherence tomography.

ClinicalTrials.gov: NCT00133952

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Eli Lilly and Company

2005 - 2008

C-03-15 - An open label evaluation of long term efficacy and safety of posterior juxtascleral injections of anecortave acetate 15mg in patients with subfoveal exudative age-related macular degeneration.

ClinicalTrials.gov: NCT00065728

Researcher

Funders: Alcon Research Ltd

2005 - 2007

EOP1012 - Phase IIIb/IV Trial to Compare Safety and Efficacy of Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 6wks for 102wks, to Pegaptanib Sodium Plus Photodynamic Therapy (PDT) With Visudyne, in Patients With Exudative AMD.

ClinicalTrials.gov: NCT00134667

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Eyetech Pharmaceuticals

2005 - 2009

GENEVA / 206207-008 - A Six- Month Multicenter, Randomized, Controlled Study to Assess the safety and Efficacy of 700ug and 350ug Dexamethasone (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following CRVO or BRVO.

ClinicalTrials.gov: NCT00168324

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Allergan AG

2005 - 2005

EOP1011 - A Phase II study Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO.

ClinicalTrials.gov: NCT00088283

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Eyetech Pharmaceuticals

2004 - 2006

OPTIMUS - Caracterização dos mecanismos de resolução do edema macular diabético após fotocoagulação por laser.

POCTI/CBO/43061/2001

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Fundação para a Ciência e a Tecnologia

2004 - 2009

C-02-20 - A five-year, multicenter, open-label study to evaluate the safety of once-daily evening instillation of travoprost 0,004% eyedrops (Travatran®) in subjects with open-angle glaucoma or ocular hypertension.

ClinicalTrials.gov: NCT00051168

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alcon Research Ltd

2004 - 2005

EOP1005 - A phase II study to establish safety and preliminary efficacy of intravitreal injections of EYE001 (Anti-VEGF Pegylated Aptamer), given every 6 weeks for 12 to 30 weeks to patients with CSME.

ClinicalTrials.gov: NCT00040313

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Eyetech Pharmaceuticals

2004 - 2005

POOL / CBPD952B2401 - An open-label, multicenter, phase IV study of the effect of Visudyne therapy in subjects with occult with no classic choroidal neovascularization secondary to Age-related Macular Degeneration.

ClinicalTrials.gov: NCT00135837

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Novartis Pharmaceuticals

2004 - 2007

C-02-27 - An evaluation of efficacy and safety of posterior juxtascleral injections of anecortave acetate 15mg (0.5ml of 30 mg/ml sterile suspension) vs vehicle in patients with subfoveal choroidal neovascularization due to exudative AMD.

ClinicalTrials.gov: NCT00051129

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alcon Research Ltd

2004 - 2008

C-02-60 - An evaluation of efficacy of posterior juxtascleral administration of Anecortave Acetate for depot suspension (15mg or 30mg) versus sham administrations in patients at risk for developing sight-threatening CNV due to exudative AMD.

ClinicalTrials.gov: NCT00307398

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Alcon Research Ltd

2004 - 2010

MBDL / B7A-MC-MBDL - Reduction in the Occurrence of center-threatening diabetic macular edema.

ClinicalTrials.gov: NCT00090519

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Eli Lilly and Company

2004 - 2004

LT1910-T02F0301 - Comparison of Efficacy and safety of Unpreserved vs Preserved Dexamethasone Phosphate 0.1% eye drops in controlling post-operative inflammation after cataract surgery. Evaluation of inflammation using a Laser Flare Meter.

LT1910-T02F0301

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Laboratoires Théa

2004 - 2007

EOP1003 - A phase II/III study to establish safety and efficacy of intravitreal injections of eye001 (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative AMD.

ClinicalTrials.gov: NCT00321997

Researcher

Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Funders: Eyetech Pharmaceuticals